These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

178 related items for PubMed ID: 38240765

  • 1. Efficacy and safety of infliximab in the treatment of Kawasaki disease: A systematic review and meta-analysis.
    Wang L, He M, Wang W, Li S, Zhao G.
    Eur J Pediatr; 2024 Apr; 183(4):1765-1776. PubMed ID: 38240765
    [Abstract] [Full Text] [Related]

  • 2. Intravenous immunoglobulin for the treatment of Kawasaki disease.
    Broderick C, Kobayashi S, Suto M, Ito S, Kobayashi T.
    Cochrane Database Syst Rev; 2023 Jan 25; 1(1):CD014884. PubMed ID: 36695415
    [Abstract] [Full Text] [Related]

  • 3. Infliximab Plus Intravenous Immunoglobulin (IVIG) Versus IVIG Alone as Initial Therapy in Children With Kawasaki Disease Presenting With Coronary Artery Lesions: Is Dual Therapy More Effective?
    Jone PN, Anderson MS, Mulvahill MJ, Heizer H, Glodé MP, Dominguez SR.
    Pediatr Infect Dis J; 2018 Oct 25; 37(10):976-980. PubMed ID: 29461447
    [Abstract] [Full Text] [Related]

  • 4. Higher efficacy of infliximab than immunoglobulin on Kawasaki disease, a meta-analysis.
    Li X, Tang Y, Ding Y, Chen Y, Hou M, Sun L, Qian G, Qin L, Lv H.
    Eur J Pharmacol; 2021 May 15; 899():173985. PubMed ID: 33652059
    [Abstract] [Full Text] [Related]

  • 5. Pharmacologic interventions for Kawasaki disease in children: A network meta-analysis of 56 randomized controlled trials.
    Lei WT, Chang LS, Zeng BY, Tu YK, Uehara R, Matsuoka YJ, Su KP, Lee PC, Cavalcante JL, Stubbs B, Lin PY, Wu YC, Hsu CW, Chen TY, Chen YW, Yeh PY, Sun CK, Tseng PT, Kao YH.
    EBioMedicine; 2022 Apr 15; 78():103946. PubMed ID: 35306339
    [Abstract] [Full Text] [Related]

  • 6. Indirect-comparison meta-analysis of treatment options for patients with refractory Kawasaki disease.
    Chan H, Chi H, You H, Wang M, Zhang G, Yang H, Li Q.
    BMC Pediatr; 2019 May 17; 19(1):158. PubMed ID: 31101091
    [Abstract] [Full Text] [Related]

  • 7. Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trial.
    Burns JC, Roberts SC, Tremoulet AH, He F, Printz BF, Ashouri N, Jain SS, Michalik DE, Sharma K, Truong DT, Wood JB, Kim KK, Jain S, KIDCARE Multicenter Study Group.
    Lancet Child Adolesc Health; 2021 Dec 17; 5(12):852-861. PubMed ID: 34715057
    [Abstract] [Full Text] [Related]

  • 8. TNF-α blockers for the treatment of Kawasaki disease in children.
    Yamaji N, da Silva Lopes K, Shoda T, Ishitsuka K, Kobayashi T, Ota E, Mori R.
    Cochrane Database Syst Rev; 2019 Aug 16; 8(8):CD012448. PubMed ID: 31425625
    [Abstract] [Full Text] [Related]

  • 9. The Kawasaki Disease Comparative Effectiveness (KIDCARE) trial: A phase III, randomized trial of second intravenous immunoglobulin versus infliximab for resistant Kawasaki disease.
    Roberts SC, Jain S, Tremoulet AH, Kim KK, Burns JC, KIDCARE Multicenter Study Group, Anand V, Anderson M, Ang J, Ansusinha E, Arditi M, Ashouri N, Bartlett A, Chatterjee A, DeBiasi R, Dekker C, DeZure C, Didion L, Dominguez S, El Feghaly R, Erdem G, Halasa N, Harahsheh A, Jackson MA, Jaggi P, Jain S, Jone PN, Kaushik N, Kurio G, Lillian A, Lloyd D, Manaloor J, McNelis A, Michalik DE, Newburger J, Newcomer C, Perkins T, Portman M, Romero J, Ronis T, Rowley A, Schneider K, Schuster J, Tejtel SKS, Sharma K, Simonsen K, Szmuszkovicz J, Truong D, Wood J, Yeh S.
    Contemp Clin Trials; 2019 Apr 16; 79():98-103. PubMed ID: 30840903
    [Abstract] [Full Text] [Related]

  • 10. Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial.
    Tremoulet AH, Jain S, Jaggi P, Jimenez-Fernandez S, Pancheri JM, Sun X, Kanegaye JT, Kovalchin JP, Printz BF, Ramilo O, Burns JC.
    Lancet; 2014 May 17; 383(9930):1731-8. PubMed ID: 24572997
    [Abstract] [Full Text] [Related]

  • 11. Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease.
    Burns JC, Best BM, Mejias A, Mahony L, Fixler DE, Jafri HS, Melish ME, Jackson MA, Asmar BI, Lang DJ, Connor JD, Capparelli EV, Keen ML, Mamun K, Keenan GF, Ramilo O.
    J Pediatr; 2008 Dec 17; 153(6):833-8. PubMed ID: 18672254
    [Abstract] [Full Text] [Related]

  • 12. Intravenous Immunoglobulin Gamma (IVIG) versus IVIG Plus Infliximab in Young Children with Kawasaki Disease.
    Han CL, Zhao SL.
    Med Sci Monit; 2018 Oct 11; 24():7264-7270. PubMed ID: 30307902
    [Abstract] [Full Text] [Related]

  • 13. Current knowledge of TNF-α monoclonal antibody infliximab in treating Kawasaki disease: a comprehensive review.
    Chen J, Liao J, Xiang L, Zhang S, Yan Y.
    Front Immunol; 2023 Oct 11; 14():1237670. PubMed ID: 37936712
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and limitation of infliximab treatment for children with Kawasaki disease intractable to intravenous immunoglobulin therapy: report of an open-label case series.
    Mori M, Imagawa T, Hara R, Kikuchi M, Hara T, Nozawa T, Miyamae T, Yokota S.
    J Rheumatol; 2012 Apr 11; 39(4):864-7. PubMed ID: 22337241
    [Abstract] [Full Text] [Related]

  • 15. Immune-monitoring in Kawasaki disease patients treated with infliximab and intravenous immunoglobulin.
    Burns JC, Song Y, Bujold M, Shimizu C, Kanegaye JT, Tremoulet AH, Franco A.
    Clin Exp Immunol; 2013 Dec 11; 174(3):337-44. PubMed ID: 23901839
    [Abstract] [Full Text] [Related]

  • 16. Infliximab as a second-line therapy for children with refractory Kawasaki disease: A systematic review and meta-analysis of randomized controlled trials.
    Kabbaha S, Milano A, Aldeyab MA, Thorlund K.
    Br J Clin Pharmacol; 2023 Jan 11; 89(1):49-60. PubMed ID: 36169097
    [Abstract] [Full Text] [Related]

  • 17. Comparison of second-line therapy in IVIg-refractory Kawasaki disease: a systematic review.
    Crayne CB, Mitchell C, Beukelman T.
    Pediatr Rheumatol Online J; 2019 Nov 27; 17(1):77. PubMed ID: 31775898
    [Abstract] [Full Text] [Related]

  • 18. [Efficacy and safety of glucocorticoids in addition to intravenous immunoglobulin in the initial treatment of Kawasaki disease: a meta-analysis of randomized trials].
    Hu JW, Zhou ZS, Yang L, Zheng CN, Wang KD.
    Zhonghua Yi Xue Za Zhi; 2011 May 17; 91(18):1259-64. PubMed ID: 21756798
    [Abstract] [Full Text] [Related]

  • 19. Infliximab versus intravenous immunoglobulin for refractory Kawasaki disease: a phase 3, randomized, open-label, active-controlled, parallel-group, multicenter trial.
    Mori M, Hara T, Kikuchi M, Shimizu H, Miyamoto T, Iwashima S, Oonishi T, Hashimoto K, Kobayashi N, Waki K, Suzuki Y, Otsubo Y, Yamada H, Ishikawa C, Kato T, Fuse S.
    Sci Rep; 2018 Jan 31; 8(1):1994. PubMed ID: 29386515
    [Abstract] [Full Text] [Related]

  • 20. Infliximab for intensification of primary therapy for patients with Kawasaki disease and coronary artery aneurysms at diagnosis.
    Miyata K, Bainto EV, Sun X, Jain S, Dummer KB, Burns JC, Tremoulet AH.
    Arch Dis Child; 2023 Oct 31; 108(10):833-838. PubMed ID: 37258054
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.